Four-year follow up data are now available from the CheckMate 214 clinical trial with the nivolumab plus ipilimumab combination in patients with metastatic renal cell carcinoma (RCC). These data show an improvement in progression-free and overall survival with the nivolumab plus ipilimumab combination compared to sunitinib in the intermediate-/poor-risk patient groups. The durability of the responses with the combination was notable in all patients, including those with favourable risk. However, overall survival results remained inconclusive in patients with favourable risk RCC.
The follow-up data confirm that the nivolumab plus ipilimumab combination remains a reasonable first-line option for patients with intermediate-/poor-risk metastatic RCC, with significant survival benefit and durable responses as shown by the long-term follow-up results.